Comparing P-Selectin (CD62P) expression in patients receiving non-leukodepleted vs leukodepleted thrombocyte concentrates
Abstract: Thrombocyte concentrate
(TC) transfusion is an important supportive therapy in patients with
thrombocytopenia. The risks in platelet transfusions may be related to the
content of TC including the contaminant leukocytes. The aim of this study was
to assess the risk of increased level of P-Selectin (CD62P) expression of
non-leukodepleted TC transfusions.This was a quasi-experimental study. Subjects
were children patients aged 1-18 years who received a non-leukodepleted or a
leukodepleted TC transfusions. Comparison of the proportion of increased expression of CD62P in both groups
expressed as relative risk. The subjects consisted of 51 patients who received
non-leukodepleted and 52 patients who received leukodepleted TC transfusions.
The risk of increased expression of CD62P in patients receiving
non-leukodepleted TC transfusions were 2.38 (95%CI:1.60-3.53) times higher than
those who received leukodepleted TC. Non-leukodepleted have significant higher
risks of increased CD62P expression than leukodepleted TC transfusions.
Keywords: thrombocyte
conentrate – transfusion – CD62P expression - thrombocytopenia – adverse effect
Author: Teguh Triyono
Journal Code: jpkedokterangg170283
